Overview
Background
Dr Brett Hughes graduated from the University of NSW with a Bachelor of Medical Science and Bachelor of Medicine and Surgery in 1997. He completed his postgraduate training in Canberra and Brisbane and was admitted as a Fellow of the Australian College of Physicians as a Specialist Medical Oncologist in 2005.
Dr Hughes is currently a Senior Staff Specialist Medical Oncologist at the RBWH and TPCH. He is also an Associate Professor at the University of Queensland since 2015. As the previous Clinical Director of Oncology (201-2017) and current Cancer Care Services Research lead at TPCH, Dr Hughes has established both an independent TPCH Oncology unit and continuing TPCH’s reputation as a lung cancer research centre of excellence.
Dr Hughes is an active senior member of the Thoracic Oncology Group Australasia (TOGA) and the Trans Tasman Radiation Oncology Group (TROG). He is also heavily involved in many pivotal multicentre trials of cancer therapy at both TPCH and RBWH with his principal research interests in Lung cancer, Head & Neck cancer, Mesothelioma, cutaneous SCC and Thyroid cancer. He has published over 100 peer review papers. Dr Hughes is also involved in undergraduate and post graduate teaching in his fields of research interest.
Availability
- Associate Professor Brett Hughes is:
- Available for supervision
Fields of research
Works
Search Professor Brett Hughes’s works on UQ eSpace
2022
Journal Article
Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study
Jiang, Yingying, Shi, Yue, Liu, Yiling, Wang, Zihan, Ma, Yuxin, Shi, Xinhong, Lu, Lin, Wang, Zhitong, Li, Hang, Zhang, Yushu, Liu, Caolu, Zhang, Shaorui, Zhong, Zhihao, Lu, Jianwei, Shi, Meiqi, Shen, Bo, Zhou, Guoren, Yin, Rong, Galetta, Domenico, Grenda, Anna, Romero, Atocha, Hughes, Brett G. M., Chen, Cheng, Wang, Xiaohua and Feng, Jifeng (2022). Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study. Translational Lung Cancer Research, 11 (12), 2521-2538. doi: 10.21037/tlcr-22-857
2022
Conference Publication
High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissue signatures associated with therapy response
Kulasinghe, Arutha, Sadeghirad, Habib, Liu, Ning, Monkman, James, Tan, Chin Wee, Cooper, Caroline, Church, Sarah, Schneider, Fabian, Thaagard, Jeppe, Mansfield, James, O’byrne, Kenneth, Davis, Melissa and Hughes, Brett (2022). High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissue signatures associated with therapy response. SITC 37th Annual Meeting (SITC 2022), Boston, MA United States, 8–12 November 2022. London, United Kingdom: BMJ Group. doi: 10.1136/jitc-2022-sitc2022.0117
2022
Conference Publication
The role of thoracic radiotherapy (TRT) in the era of chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC)
Turner, Cassie L., Prasetio, Tito E., O'Berine, Shannon, Anderson, Georgina, Hughes, Brett G. M., Vignarajah, Dinesh, Castelli, Joanne, Lwin, Zarnie, Houston, Kathleen and Chan, Bryan A. (2022). The role of thoracic radiotherapy (TRT) in the era of chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC). HOBOKEN: WILEY.
2022
Journal Article
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 Study
Harrington, Kevin J., Burtness, Barbara, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Brana, Irene, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Lin, Jianxin, Gumuscu, Burak, Swaby, Ramona F. and Rischin, Danny (2022). Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 Study. Journal of Clinical Oncology, 41 (4), 790-802. doi: 10.1200/jco.21.02508
2022
Journal Article
Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma
Gross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo B., Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G.M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Kaufman, Howard L., Seebach, Frank, Lowy, Israel, Yoo, Suk-Young, Mathias, Melissa, Fenech, Keilah, Han, Hyunsil, Fury, Matthew G. and Rischin, Danny (2022). Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. New England Journal of Medicine, 387 (17), 1557-1568. doi: 10.1056/nejmoa2209813
2022
Journal Article
Prevalence and impact of computed tomography-defined sarcopenia on survival in patients with human papillomavirus-positive oropharyngeal cancer: a systematic review
Edwards, Anna, Hughes, Brett G M, Brown, Teresa and Bauer, Judith (2022). Prevalence and impact of computed tomography-defined sarcopenia on survival in patients with human papillomavirus-positive oropharyngeal cancer: a systematic review. Advances in Nutrition, 13 (6), 2433-2444. doi: 10.1093/advances/nmac076
2022
Journal Article
Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: Subgroup analysis by programmed death ligand-1 combined positive score
Burtness, Barbara, Rischin, Danny, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Brana, Irene, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Ge, Joy, Swaby, Ramona F., Gumuscu, Burak and Harrington, Kevin (2022). Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: Subgroup analysis by programmed death ligand-1 combined positive score. Journal of Clinical Oncology, 40 (21), 2321-2332. doi: 10.1200/jco.21.02198
2022
Journal Article
Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer
Kapeleris, Joanna, Bark, Juliana Müller, Ranjit, Shanon, Irwin, Darryl, Hartel, Gunter, Warkiani, Majid Ebrahimi, Leo, Paul, O’Leary, Connor, Ladwa, Rahul, O'Byrne, Kenneth, Hughes, Brett G.M. and Punyadeera, Chamindie (2022). Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer. Heliyon, 8 (7) e09971, 1-9. doi: 10.1016/j.heliyon.2022.e09971
2022
Journal Article
Application of circulating tumour cells to predict response to treatment in head and neck cancer
Zhang, Xi, Ekanayake Weeramange, Chameera, Hughes, Brett G. M., Vasani, Sarju, Liu, Zhen Yu, Warkiani, Majid Ebrahimi, Hartel, Gunter, Ladwa, Rahul, Thiery, Jean Paul, Kenny, Liz and Punyadeera, Chamindie (2022). Application of circulating tumour cells to predict response to treatment in head and neck cancer. Cellular Oncology, 45 (4), 1-13. doi: 10.1007/s13402-022-00681-w
2022
Journal Article
A randomized, double-blind noninferiority study to evaluate the efficacy of the cabozantinib tablet at 60 mg per day compared with the cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancer
Capdevila, Jaume, Klochikhin, Arkadiy, Leboulleux, Sophie, Isaev, Pavel, Badiu, Corin, Robinson, Bruce, Hughes, Brett G.M., Keam, Bhumsuk, Parnis, Francis, Elisei, Rossella, Gajate, Pablo, Gan, Hui K., Kapiteijn, Ellen, Locati, Laura, Mangeshkar, Milan, Faoro, Leonardo, Krajewska, Jolanta and Jarzab, Barbara (2022). A randomized, double-blind noninferiority study to evaluate the efficacy of the cabozantinib tablet at 60 mg per day compared with the cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancer. Thyroid, 32 (5), 515-524. doi: 10.1089/thy.2022.0027
2022
Journal Article
Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas
Sadeghirad, Habib, Monkman, James, Mehdi, Ahmed M., Ladwa, Rahul, O’Byrne, Ken, Hughes, Brett G. M. and Kulasinghe, Arutha (2022). Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas. Frontiers in Immunology, 13 895513, 1-11. doi: 10.3389/fimmu.2022.895513
2022
Journal Article
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
Rischin, Danny, Harrington, Kevin J., Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Braña, Irene, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Hong, Ruey-Long, Mendoza, René Gonzalez, Jia, Liyi, Chirovsky, Diana, Norquist, Josephine, Jin, Fan and Burtness, Barbara (2022). Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncology, 128 105815, 1-12. doi: 10.1016/j.oraloncology.2022.105815
2022
Journal Article
The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review
Edwards, Anna, Brown, Teresa, Hughes, Brett G. M. and Bauer, Judy (2022). The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review. Supportive Care in Cancer, 30 (9), 7191-7204. doi: 10.1007/s00520-022-07056-9
2022
Journal Article
A randomized study of Lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer
Brose, Marcia S., Panaseykin, Yury, Konda, Bhavana, de la Fouchardiere, Christelle, Hughes, Brett G. M., Gianoukakis, Andrew G., Joo Park, Young, Romanov, Ilia, Krzyzanowska, Monika K., Leboulleux, Sophie, Binder, Terri A., Dutcus, Corina, Xie, Ran and Taylor, Matthew H. (2022). A randomized study of Lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 107 (3), 776-787. doi: 10.1210/clinem/dgab731
2022
Journal Article
Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment
Ahern, Elizabeth, Brown, Teresa E, Campbell, Louise, Hughes, Brett G. M., Banks, Merrilyn D., Lin, Charles Y., Kenny, Lizbeth M. and Bauer, Judith D. (2022). Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment. British Journal of Nutrition, 129 (3) PII S0007114522000435, 1-25. doi: 10.1017/S0007114522000435
2022
Journal Article
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
Peters, S., Pujol, J. L., Dafni, U., Dómine, M., Popat, S., Reck, M., Andrade, J., Becker, A., Moro-Sibilot, D., Curioni-Fontecedro, A., Molinier, O., Nackaerts, K., Insa Mollá, A., Gervais, R., López Vivanco, G., Madelaine, J., Mazieres, J., Faehling, M., Griesinger, F., Majem, M., González Larriba, J. L., Provencio Pulla, M., Vervita, K., Roschitzki-Voser, H., Ruepp, B., Mitchell, P., Stahel, R. A., Le Pechoux, C., De Ruysscher, D. ... Califano, R. (2022). Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Annals of Oncology, 33 (1), 67-79. doi: 10.1016/j.annonc.2021.09.011
2022
Journal Article
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial
Kok, Peey Sei, Forde, Patrick M., Hughes, Brett, Sun, Zhuoxin, Brown, Chris, Ramalingam, Suresh, Cook, Alistair, Lesterhuis, Willem Joost, Yip, Sonia, O'Byrne, Ken, Pavlakis, Nick, Brahmer, Julie, Anagnostou, Valsamo, Ford, Kate, Fitzpatrick, Karen, Bricker, Alison, Cummins, Michelle M., Stockler, Martin and Nowak, Anna K. (2022). Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial. BMJ Open, 12 (1) e057663, e057663. doi: 10.1136/bmjopen-2021-057663
2022
Journal Article
Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008))
Hughes, B. G.M., Munoz-Couselo, E., Mortier, L., Bratland, , Gutzmer, R., Roshdy, O., González Mendoza, R., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R. F. and Grob, J. J. (2022). Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008)). Annals of Oncology, 33 (8), 853-853. doi: 10.1016/j.annonc.2022.05.517
2022
Journal Article
Understanding the tumor microenvironment in head and neck squamous cell carcinoma
Rad, Habib Sadeghi, Shiravand, Yavar, Radfar, Payar, Ladwa, Rahul, Perry, Chris, Han, Xiaoyuan, Warkiani, Majid Ebrahimi, Adams, Mark N., Hughes, Brett G.M., O'Byrne, Ken and Kulasinghe, Arutha (2022). Understanding the tumor microenvironment in head and neck squamous cell carcinoma. Clinical & Translational Immunology, 11 (6) e1397, e1397. doi: 10.1002/cti2.1397
2021
Journal Article
Evaluation of a novel pre‐treatment model of nutrition care for patients with head and neck cancer receiving chemoradiotherapy
Blake, Claire, Edwards, Anna, Treleaven, Elise, Brown, Teresa, Hughes, Brett, Lin, Charles, Kenny, Lizbeth, Banks, Merrilyn and Bauer, Judy (2021). Evaluation of a novel pre‐treatment model of nutrition care for patients with head and neck cancer receiving chemoradiotherapy. Nutrition and Dietetics, 79 (2), 206-216. doi: 10.1111/1747-0080.12714
Supervision
Availability
- Associate Professor Brett Hughes is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
The changing face of head and neck cancer: addressing and advancing best-practice nutritional care to improve outcomes for patients with human papillomavirus-associated disease
Associate Advisor
-
Doctor Philosophy
Developing predictive biomarkers for immunotherapy using deep spatial profiling
Associate Advisor
Other advisors: Associate Professor Arutha Kulasinghe
Completed supervision
-
2025
Doctor Philosophy
The investigation of the tumour microenvironment in head and neck squamous cell carcinoma to identify predictive biomarkers of response to immunotherapy
Associate Advisor
Other advisors: Dr Quan Nguyen, Associate Professor Arutha Kulasinghe
Media
Enquiries
For media enquiries about Associate Professor Brett Hughes's areas of expertise, story ideas and help finding experts, contact our Media team: